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ABSTRACT
Adjustable transgene expression is considered key
for next-generation molecular interventions in gene
therapy scenarios, therapeutic reprogramming of
clinical cell phenotypes for tissue engineering and
sophisticated gene-function analyses in the post-
genomic era. We have designed a portfolio of latest
generation self-inactivating human (HIV-derived) and
non-human (EIAV-based) lentiviral expression vec-
tors engineered for streptogramin-adjustable ex-
pression of reporter (AmySDS, EYFP, SAMY, SEAP),
differentiation-modulating (human C/EBP-a) and
therapeutic (human VEGF) transgenes in a variety
of rodent (CHO-K1, C2C12) and human cell lines
(HT-1080, K-562), human and mouse primary cells
(NHDF, PBMC, CD4+) as well as chicken embryos.
Lentiviral design concepts include (i) binary systems
harboring constitutive streptogramin-dependent
transactivator (PIT) and PIT-responsive transgene
expression units on separate lentivectors; (ii) strepto-
gramin-responsive promoters (PPIR8) placed 5
0 of
desired transgenes; (iii) within modified enhancer-
free 30-long terminal repeats; and (iv) bidirectional
autoregulated configurations providing streptogra-
min-responsive transgene expression in a lentiviral
one-vector format. Rigorous quantitative analysis
revealed HIV-based direct PPIR-transgene configura-
tions to provide optimal regulation performance for (i)
adjustable expression of intracellular and secreted
product proteins, (ii) regulated differential differentia-
tion of muscle precursor cell lines into adipocytes or
osteoblasts and (iii) conditional vascularization fine-
tuning in chicken embryos. Similar performance
could be achieved by engineering streptogramin-
responsive transgene expression into an auto-
regulated one-vector format. Powerful transduction
systems equipped with adjustable transcription
modulation options are expected to greatly advance
sophisticated molecular interventions in clinically
and/or biotechnologically relevant primary cells and
cell lines.
INTRODUCTION
Based on their ability to transduce a wide variety of difficult-
to-transfect quiescent as well as mitotically active cell types
and target tissues without eliciting significant humoral
immune responses, transgenic lentiviral particles are currently
at the forefront of clinical engineering initiatives (1–7).
Although stripped of some 60% of their genomes including
all accessory genes and produced by reassembly using multi-
ply attenuated split-genome packaging systems, safety
concerns about the clinical use of human immunodeficiency
virus (HIV)-derived transduction systems are ongoing. In their
latest generation, HIV-1-based lentiviral transduction systems
consist of (i) helper plasmid(s) encoding gag (encoding major
structural proteins), pol (coding for lentivirus-specific
enzymes) and rev (a regulator of gag/pol expression and
nuclear export of virus RNA); (ii) a vsv-g expression vector
promoting pantropic transduction of pseudotyped lentiviral
particles; and (iii) the actual transgene(s)-encoding lentivector
which remains the only genetic material transferred to desired
target cells (8).
The lentivector typically contains the transgene expression
cassette flanked by cis-acting elements required for encapsi-
dation, reverse transcription and integration: the extended
packaging signal (y+), the polypurine tracts (PPT, cPPT),
50- and 30-long terminal repeats (50- and 30-LTRs) as well
as env-derived sequences encompassing the Rev response
element (RRE) (8–12). To prevent transcriptional interference
with transgene expression and provirus-flanking chromosomal
cistrons, most lentivectors are self-inactivating (SIN), charac-
terized by a 30-LTR-located enhancer deletion (30LTRDU3)
resulting in the elimination of 50-LTR-based transcriptional
activities following reverse transcription and integration
(13–16). Following the generic design principle of pioneering
HIV-based lentiviral transduction systems, a variety of
different non-human/non-primate lentivirus derivatives have
recently been reported to transduce mammalian cells at similar
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efficiencies and tropism while successfully addressing HIV-
associated safety concerns (17–22). Whatever lentiviral trans-
duction system will eventually prevail in the clinics it will
have to be compatible with transcription control modalities to
titrate protein pharmaceuticals into their therapeutic window
and/or adjust their levels to daily changing dosing regimes
(23–25).
We have recently developed a human-compatible transcrip-
tion control system (PIP) responsive to clinically licensed
antibiotics of the streptogramin class (e.g. pristinamycin) (26).
A streptogramin-dependent transactivator (PIT), designed by
fusing the Streptomyces coelicolor pristinamycin-induced
protein to the Herpes simplex-derived VP16 transactivation
domain (PIP-VP16), binds and activates chimeric promoters
(PPIR8), assembled by cloning tandem PIT-specific operator
modules 50 of a minimal eukaryotic promoter, in a pristina-
mycin-adjustable manner (26–28).
Capitalizing on recent advances in lentivector design (29)
we have engineered a variety of isogenic lentiviral particles for
streptogramin-responsive transgene expression and validated
their performance in different human primary cells, cell lines
as well as in chicken embryos.
MATERIALS AND METHODS
Vector design
All plasmids and oligonucleotides used in this study are listed
in Tables 1 and 2, respectively. Detailed information on
plasmid construction is also provided in Table 1.
Cell culture
Human embryonic kidney cells transgenic for simian virus 40
(SV40) large T antigen [HEK293-T; (29)], human fibro-
sarcoma cells (HT-1080; ATCC CCL-121), human peripheral
blood mononuclear cells (PBMC; kindly provided by Claudia
Ferrara), mouse CD4+ cells (kindly provided by Ivo Sonder-
egger) and C2C12PIT/tTA, a mouse myoblast cell line (C2C12;
CRL-1772) transgenic for constitutive expression of strepto-
gramin (PIT)- and tetracycline (tTA)-dependent transactiva-
tors (30), were cultivated in DMEM (Invitrogen, Carlsbad,
CA) supplemented with 10% heat-inactivated fetal calf
serum (FCS) (PAN Biotech GmbH, Aidenbach, Germany;
Cat. No. 3302-P231902), 100 U penicillin and 100 mg/ml
streptomycin (Sigma Chemicals, St. Louis, MO), 800 mg/ml
G418 (Invitrogen) (C2C12PIT/tTA only) and kept at 37
C in a
5% CO2-containing humidified atmosphere. Chinese hamster
ovary cells (CHO-K1; ATCC CCL-61) and their derivative
CHO-TWIN1108 (31) were cultivated in 10% FCS-containing
FMX-8 medium (Cell Culture Technologies GmbH, Zurich,
Switzerland) supplemented with 400 mg/ml G418. Normal
human dermal fibroblasts (NHDFs; PromoCell GmbH,
Heidelberg, Germany; Cat. No. C-12300) were cultivated
in fibroblast basal medium (PromoCell GmbH; Cat. No. C-
23210). Human chronic myelogenous leukemia cell line
K-562 (ATCC-243) was cultivated in Iscove’s modified Dul-
becco’s medium (Invitrogen) supplemented with 10% FCS.
Lentivirus production and infection
For production of replication-incompetent, SIN HIV-based
lentiviral particles, a mixture containing 94 ml DMEM, 6 ml
FuGENE6 (Roche Diagnostics AG, Rotkreuz, Switzerland),
25 mM chloroquine, 1 mg pLTR-G [encoding the pseudotyping
envelope protein VSV-G of the vesicular stomatitis virus
(11)], 1 mg pCD/NL-BH* (helper construct) (32) and 1 mg
of the desired transgene-encoding lentiviral expression vector
was co-transfected into HEK293-T cells. Likewise, the human
HIV-1-derived vectors were replaced by non-primate equine
infectious anaemia virus (EIAV) counterparts: 1 mg of envel-
ope-encoding pRV67 (19), 2 mg pONY3.1 (helper construct)
(19) and 2 mg of the engineered EIAV-derived lentivector. The
medium of HEK293-T cultures was replaced 6 h post-trans-
fection and lentiviral particles were produced for another 48 h
prior to collection from the supernatant by filtration through a
0.45 mm filter (Schleicher & Schuell GmbH, Dassel, Germany;
FP 030/2), which typically yielded titers of 2 · 107 cfu/ml
following titration on CHO-K1 cells. To prevent cross-
contamination of secreted proteins from production superna-
tants and increase overall transduction/production efficiency,
lentiviral particles were concentrated by ultracentrifugation at
25 000 r.p.m. for 2 h at 4C (Beckman Quick-Seal centrifuge
tubes; Beckman Instruments Inc., CA; Cat. No. 342413). The
pellets were resuspended in FCS-containing DMEM (see
above) to adjust viral concentrations to desired levels. Lenti-
viral particle titers were quantified by titration on CHO-K1
cells [enhanced yellow fluorescent protein (EYFP)-encoding
lentivectors] and/or using standard p24-specific enzyme-
linked immunosorbent assay (ELISA) according to the man-
ufacturer’s protocol (NEK-050; PerkinElmer, Boston, MA).
Unless stated otherwise, standard transduction experiments
included infection of 24 000 target cells seeded per well of a
12-well plate with 2 · 106 cfu lentiviral particles (10 ng of p24).
Quantification of reporter protein production
Product proteins were quantified in cell culture supernatants/
lysates three days post-transduction. AmySDS, SAMY and
secreted alkaline phosphatase (SEAP) titers were assessed
following protocols by Schlatter et al. (33) using the blue
starch Phadebas1 (AmySDS, SAMY; Pharmacia Upjohn,
Peapack, NJ) or a chemiluminescence-based assay (SEAP;
Roche Diagnostics AG). Vascular endothelial growth factor
(VEGF) production was quantified using the human VEGF-
specific DuoSet ELISA System (R&D Systems, Minneapolis,
MO) according to the manufacturer’s protocol.
Characterization of adipogenic and osteogenic cell
phenotypes
To visualize adipogenic cell phenotypes following transduc-
tion of C2C12PIT/tTA cells with pBM103-derived lentiviral
particles, transduced cells were cultured to 80% confluence
in FCS-supplemented DMEM (see above) and then transferred
to the same medium also containing 1 mM dexamethasone,
50 mM ETYA and 5 mg/ml insulin [Dex/ETYA/Insulin, DEI;
(34)]. After DEI induction for 14 days, cells were fixed for
1 h in 37% aqueous formaldehyde solution. Excess formalde-
hyde was removed by rinsing three times with ddH2O for 30 s
prior to immersion of cells in a Oil Red O working solution for
30 min [12 ml Oil Red O stock solution in 8 ml ddH2O; Oil
Red O stock solution: 500 mg Oil Red O (Fluka Chemie,
Buchs SG, Switzerland) dissolved in 100 ml 60% triethyl-
phosphate (Fluka Chemie]. Subsequently, cells were washed
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Table 1. Plasmids used and designed in this study
Plasmids Description and cloning strategy Reference or source
pBiRex4 Streptogramin-responsive bidirectional expression vector (pAI-EYFP PhCMVmin-PTR-Phsp70min!PIT-pA) (27)
pBP33 Streptogramin-responsive SEAP expression vector (PPIR8-SEAP-IRES-pA) (28)
pCD/NL-BH*a HIV-1-derived gag/pol-encoding helper plasmid (32)
pCFl Dual-regulated expression vector encoding c/ebp-a Unpublished data
pCF19 Plasmid containing SEAP cassette (30)
pCF77 Vector containing a pAI-MCS-pAII cassette Unpublished data
pJK16 HIV-1-derived lentiviral expression vector encoding a PhCMV-driven EYFP expression unit (5
0LTR-y+-
oriSV40-cPPT-RRE-PhCMV-EYFP-3
0LTRDU3)
Unpublished data
pLentiModule4a Modular lentiviral expression vector encoding PhCMV-driven EYFP expression unit (5
0LTR-y+-cPPT-RRE-
PhCMV-EYFP-3
0LTRDU3)
(29)
pLentiModule8a Modular lentiviral expression vector encoding PhEF1a-driven SEAP expression unit (5
0LTR-y+-cPPT-RRE-
PhEF1a-SEAP-3
0LTRDU3)
(29)
pLTR-Ga Expression vector encoding VSV-G (50LTR-VSV-G-pA) (11)
pMF156 Expression vector encoding the streptogramin-dependent transactivator (PIT) (PhCMV-PIT-pA) (26)
pMF351a Lentiviral expression vector (50LTR-y+-oriSV40-cPPT-RRE-MCSI-PhCMV-EYFP-MCSII-30LTRDU3) (29)
pMF356a Lentiviral expression vector (50LTR-y+-oriSV40-cPPT-RRE-MCS-30LTRDU3) (29)
pMF359a pMF356-derived lentiviral expression vector (29)
pMF364a Lentiviral expression vector (50LTR-y+-oriSV40-cPPT-RRE -MCSI-PhEF1a-SAMY-MCSII-30LTRDU3) Unpublished data
pMF392a Lentiviral expression unit encoding the streptogramin-dependent transactivator (PIT). PIT was excised from
pMF156 by EcoRI/Xbal and ligated into the corresponding sites (EcoRI/Spel) of pMF359. (50LTR-y+-
oriSV40-cPPT-RRE-PhEF1a-PIT-3
0LTRDU3)
This work
pONY3.1b EIAV-derived helper plasmid (PhCMV-tat-gag-pol-tat-S2-DEnv-rev30LTRDU3) (17)
pONY8.0Gb EIAV-derived lentiviral expression vector (ECMV-R-U5-MCS-DEnv-30LTRDU3) (19)
pRV67 Expression vector encoding VSV-G (PhCMV-VSV-G-pA) (17)
pSS 185 Expression vector encoding SAMY (PhCMV-SAMY-pA) (33)
pSS 189 Expression vector encoding amySDS (PhCMV–amySDS-pA) (33)
pBM43a Lentiviral expression vector encoding a PhEF1a-driven VEGF121 expression cassette (5
0LTR-y+-oriSV40-cPPT-
RRE-PhEFla-VEGF121-3
0LTRDU3)
(29)
pBM57a PhCMV was eliminated from pJK16 by XmaI/AgeI-mediated deletion (5
0LTR-y+-oriSV40-cPPT-RRE-EYFP-
30LTRDU3)
This work
pBM60a PPIR8 was PCR-amplified from pBP33 using OBM27/OBM28, PmeI-restricted and cloned into the
corresponding site (PmeI) of pBM57 (50LTR-y+-oriSV40-cPPT-RRE-EYFP-30LTRDU3I-PPIR8-30LTRDU3II)
This work
pBM76b PhCMV-EYFP was excised from pMF351 by XbaI/KpnI and cloned into the corresponding sites (XbaI/KpnI) of
pONY8.0G (ECMV-R-U5-PhCMV-EYFP-DEnv-30LTRDU3)
This work
pBM80b PhCMV-EYFP was eliminated from pBM76 by NotI-mediated deletion (ECMV-R-U5-MCS-D Env-30LTRDU3) This work
pBM84a AmySDS was PCR-amplified from pSS189 using OBM37/OBM38, AscI/SwaI-restricted and cloned into the
corresponding sites (AscI/SwaI) of pBM60 (50LTR-y+-oriSV40-cPPT-RRE-amySDS-30LTRDU3I-PPIR8-
30LTRDU3II)
This work
pBM85a SAMY was PCR-amplified from pSS185 using OBM37/OBM38, AscI/SwaI-restricted and cloned into the
corresponding sites (AscI/SwaI) of pBM60 (50LTR-y+-oriSV40-cPPT-RRE-SAMY-30LTRDU3I-PPIR8-
30LTRDU3II)
This work
pBM90a PPIR8 was eliminated from pBM84 by PmeI-mediated deletion (5
0LTR-y+-oriSV40-cPPT-RRE-amySDS-
30LTRDU3)
This work
pBM91a PPIR8 was eliminated from pBM85 by PmeI-mediated deletion (5
0LTR-y+-oriSV40-cPPT-RRE-SAMY-
30LTRDU3)
This work
pBM92a c/ebp-a was excised from pCFl by BamHI/ClaI and cloned into the corresponding sites (ClaI/BamHI) of
pCF77 (pAI-c/ebp-a-pAII) in antisense orientation
This work
pBM93a pAI-EYFP PhCMVmin-PTR-Phsp70min!PIT-pAII was excised from pBiRex4 by EcoRV/XbaI and cloned into
the compatible sites (SmaI/SpeI) of pMF356 (50LTR-y+-oriSV40-cPPT-RRE-pAI-EYFP PhCMVmin-PTR-
Phsp70min!PIT-pAII -30LTRDU3)
This work
pBM94a PPIR8 was PCR-amplified from pBP33 using OBM39/OBM40, AscI/MluI-restricted and cloned into the
compatible AscI site of pBM57 (50LTR-y+-oriSV40-cPPT-RRE-PPIR8-EYFP-30LTRDU3)
This work
pBM95a c/ebp-awas excised from pBM92 by ClaI/MluI and cloned in sense orientation into the compatible sites (AscI/
BstBI) of pBM60 (50LTR-y+-oriSV40-cPPT-RRE-c/ebp-a-30 LTRDU3I-PPIR8-30LTRDU3II)
This work
pBM96a PPIR8 was PCR-amplified from pBP33 using OBM39/OBM40, AscI/MluI restricted and cloned into the
compatible AscI site of pBM91 (50LTR-y+-oriSV40-cPPT-RRE-PPIR8-SAMY-30LTRDU3)
This work
pBM97a PPIR8 was PCR-amplified from pBP33 using OBM39/OBM40, AscI/MluI-restricted and cloned into the
compatible AscI site of pBM90 (50LTR-y+-oriSV40-cPPT-RRE-PPIR8-amySDS-30LTRDU3)
This work
pBM98a pAI-EYFP PhCMVmin-PTR-Phsp70min!PIT was excised from pBiRex4 by EcoRV/PsiI and cloned in sense
orientation into the compatible sites (HpaI/SwaI) of pMF356 (50LTR-y+-oriSV40-cPPT-RRE-pAI-
EYFP PhCMVmin-PTR-Phsp70min!PTR-30LTRDU3)
This work
pBM99b PPIR8-EYFP was excised from pBM94 by AscI/PacI and cloned into the corresponding sites (AscI/PacI) of
pBM80 (ECMV-R-U5-PPIR8-EYFP-DEnv-30LTRDU3)
This work
pBM101a PPIR8 was eliminated from pBM95 by Pmel-mediated deletion (5
0LTR-y+-oriSV40-cPPT-RRE-c/ebp-a-
30LTRDU3)
This work
pBM103a c/ebp-a was excised from pBM101 by EcoRI/NheI and cloned into the corresponding sites (EcoRI/NheI) of
pBM94 (50LTR-y+-oriSV40-cPPT-RRE-PPIR8-c/ebp-a-30LTRDU3)
This work
pBM104a VEGF121 was excised from pBM43 by EcoRI/MluI and cloned into the corresponding sites (EcoRI/MluI) of
pBM94 (50LTR-y+-oriSV40-cPPT-RRE-PPIR8-VEGF121-30LTRDU3)
This work
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three times with ddH2O for 30 s and the nuclei stained for 60 s
with Mayer’s hematoxylin (Sigma Chemicals). Finally, cells
were rinsed in ddH2O for 10 min and covered with cover slips
using 10% glycerol in PBS (35). Alkaline phosphatase-specific
staining of osteogenic cell phenotypes was visualized follow-
ing a five-day cultivation using the Sigma Kit 85 according to
the manufacturer’s instructions (Sigma Chemicals).
Transduction of chicken embryos
Experiments involving chicken embryos were conducted fol-
lowing the shell-free cultivation protocols by Djonov et al.
(36). After three days of incubation at 37C, Brown Leghorn
eggs were opened and their contents were carefully poured
into 80 mm plastic Petri dishes. The chicken embryos were
incubated at 37C in a humidified atmosphere. Recombinant
lentiviral particles (2 ml of pBM104 (8.7 · 106 cfu)- and 1 ml of
pMF392 (1.5 · 105 cfu)-derived) were co-applied locally on
top of the growing chorioallantoic membrane (CAM) at
embryonic day 9, together with 0.5 ml CellTracker
Orange CMTMR (Molecular Probes Inc., Eugene, OR;
Cat.No. C-2927) in 100 ml DMEM (final concentration 0.5 nM).
To modulate heterologous VEGF121 expression, different
amounts (0, 6, 30, 60 mg) of pristinamycin were administered
for 1 h post-transduction. On embryonic day 12, the CAMs were
examined by in vivo fluorescence microscopy following intra-
venous injection of 100 ml of 2.5% fluorescein isothiocyanate
dextran (FITC, 2 000 000; Sigma Chemicals) (37).
Fluorescence microscopy
EYFP expression in cell culture as well as FITC-stained CAM
blood vessels were visualized at 50· and 100· magnifications
using a Leica DM-RB fluorescence microscope equipped
with a Leica digital fluorescence camera DC300 FX (Leica
Microsystems AG, Heerbrugg, Switzerland) and a XF114
filter (Omega Optical Inc., Brattleboro, VT). EYFP-mediated
fluorescence was quantified using a GeniusPro (Tecan Group
Ltd, Maennedorf, Switzerland) and/or the ImageJ software
(Wayne Rasband, National Institutes of Health, http://rsb.
info.nih.gov/ij/).
Regulating antibiotics
The pristinamycin antibiotic Pyostacin1 (PI, Aventis Inc.,
Paris, France: lot no. 27404) was prepared as stock solution
of 500 mg/ml in dimethyl sulfoxide and used at a final
concentration of 2 mg/ml unless indicated otherwise.
RESULTS
HIV- and EIAV-derived lentivector configurations
for streptogramin-responsive EYFP expression
Based on the recently developed HIV-1-derived (modular)
SIN lentivector design (29), we have constructed pBM57
Table 1. Continued
Plasmids Description and cloning strategy Reference or source
pBM105a SEAP was excised from pLentiModule8 by EcoRI/NheI and cloned into the corresponding sites (EcoRI/NheI)
of pBM94(50LTR-y+-oriSV40-cPPT-RRE-PPIR8-SEAP-30LTRDU3)
This work
pBM106a EYFP PhCMVmin-PTR-Phsp70min!PIT was excised from pBiRex4 by ClaI/PsiI and cloned in sense
orientation into the compatible sites (ClaI/SwaI) of pBM356 (50LTR-y+-oriSV40-cPPT-RRE-
EYFP PhCMVmm-PTR-Phsp70min!PIT-30LTRDU3)
pBM126a pAI-SEAP PhCMVmin-PTR-Phsp70min!PIT-pA11 was excised from pCF19 by PmeI/ClaI and cloned in
antisense orientation into the compatible sites (ClaI/NruI) of pBM93 (pAI-EYFP PhCMVmin-PTR-
Phsp70min!PIT-pA11)
pBM127a pA1-SEAP PhCMVmin-PTR-Phsp70min! PIT was excised from pCF19 by PmeI/ClaI and cloned in antisense
orientation into the compatible sites (ClaI/NruI) of pBM98 (pAI-EYFP PhCMVmin-PTR-Phsp70min!PIT)
pBM128a SEAP PhCMVmin-PTR-Phsp70min!PIT was excised from pCF19 by PmeI/ClaI and cloned in antisense
orientation into the compatible sites (ClaI/NruI) of pBM106 (EYFP PhCMVmin-PTR-Phsp70min!PIT)
aHuman immunodeficiency virus (HIV)-1-derived lentiviral expression vectors.
bEquine infectious anemia virus (EIAV)-derived lentiviral expression vectors. Please consult Table 2 for indicated oligonucleotides.
Abbreviations: 30-LTR, 30-long terminal repeat; 30-LTRDU3, 30-LTR devoid of the enhancer; 30-LTRDU3I/30-LTRDU3II 30-LTRDU3 subunits; 50-LTR, 50-LTR; amyS, B.
stearothermophilus a-amylase; amySDS, B. stearothermophilus a-amylase devoid of its signal sequence; c/ebp-a, CCAAT/enhancer-binding protein alpha; cPPT,
central polypurine tract; ECMV, enhancer derived from PhCMV; EIAV, equine infectious anemia virus; EYFP, enhanced yellow fluorescent protein; HIV-1, human
immunodeficiency virus type 1; gag, lentiviral core protein; IRES, internal ribosome entry site of polioviral origin; MCS, multiple cloning site; oriSV40, simian virus
40-derived origin of replication; pA, SV40-derived polyadenylation site; pAI , pAII, minimal synthetic polyadenylation sites; PhCMV, cytomegalovirus immediate
early promoter; PhEFla, promoter of the human elongation factor la; PhCMVmin minimal version of PhCMV; Phsp70min minimal version of the Drosophila heat-shock
protein 70 promoter; PIT, streptogramin-dependent transactivator; pol, virion-associated polymerase; PPIR8, streptogramin-responsive promoter; PTR, PIT-specific
operator module; R-U5, elements of 50-/30-LTRs; Rev, specific for nuclear export of viral RNA; RRE, Rev response element; S2, EIAV-specific determinant critical
for viral replication and pathogenic properties in vivo; SAMY, B. stearothermophilus-derived secreted a-amylase; SEAP, human secreted alkaline phosphatase;
tat, LTR-specific transactivator; VEGF121, human vascular endothelial growth factor 121; VSV-G, vesicular stomatitis virus protein G; D Env, truncated EIAV
envelope-encoding gene; and y+, extended lentiviral packaging signal.
Table 2. Oligonucleotides designed for this study
Primer Sequence Restriction
sites (50!30)
OBM27 CGGTTTAAACgacgtcggagaaatagcg PmeI
OBM28 CGTGATCAGTTTAAACagctcgaattccgcgga BelI, PmeI
OBM37 CGGGCGCGCCtaagcttggtaccgagct AscI
OBM38 CGACGCGTATTTAAATaagcttcaagcataatct MluI, SwaI
OBM39 CGGGCGCGCCgacgtcggagaaatagcg AscI
OBM40 CGTGATCAACGCGTagctcgaattccgcgga BelI, MluI
Annealing sequence in lower case; sites for indicated restriction endonucleases
are underlined.
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(50LTR-y+-oriSV40-PPT-RRE-MCSI-EYFP-MCSII-30LTRDU3I-
MCSIII-30LTRDU3II), which provides convenient multiple
cloning sites (MCSI and MCSIII) for integration of promoter
elements driving an EYFP transgene (Figure 1). The optimized
streptogramin-responsive promoter [PPIR8; (28)] was either
placed within the DU3 region to support directional copy
into the 50-LTR following lentivector reverse transcription
and integration (pBM60; 50LTR-y+-oriSV40-PPT-RRE-
MCSI-EYFP-MCSII-30LTRDU3I-PPIR8-30LTRDU3II) or cloned
immediately 50 of EYFP (pBM94; 50LTR-y+-oriSV40-PPT-
R R E - P PIR8-EYFP-MCSII-3
0LTRDU3I-MCSIII-30LTRDU3II)
(Figure 2A). pBM60- and pBM94-derived lentiviral particles
were transduced into CHO-TWIN1108 constitutively expres-
sing the streptogramin-dependent transactivator [PIT; (31)],
and cultivated in the presence or absence of the regulating
streptogramin antibiotic pristinamycin I (PI). Both lentivectors
provided high-level EYFP expression in the absence of PI
whereas transgene production was completely repressed fol-
lowing addition of the regulating antibiotic (Figure 2B).
Although both promoter-transgene configurations enabled
tight regulation, qualitative assessment of EYFP expression
profiles revealed higher maximum expression levels from
PPIR8 placed 5
0 of the desired transgene rather than in the DU3
region (Figure 2B). Following the direct PPIR8-EYFP design
concept, a non-primate EIAV-based pONY8.0G-derived
lentivector (19) (pBM80; ECMV-R-U5-MCS-DEnv-30LTRDU3;
Figure 1) was engineered for streptogramin-responsive EYFP
expression (pBM99; ECMV-R-U5-PPIR8-EYFP-DEnv-30LTRDU3)
and transduced into CHO-TWIN1108. Fluorescence micro-
graph-based analysis suggested EIAV-mediated EYFP expres-
sion to be significantly lower compared to levels resulting
from HIV-based transduction (Figure 2B), which likely con-
firms reports on decreased transduction efficiency of this non-
human lentivector type in CHO cells (18). Nevertheless, this
EIAV-based lentivector design pioneers transcription modula-
tion in a non-human lentivirus configuration and combines
tight regulation with maximum expression levels acceptable
for most applications.
Comparative transgene expression profiling of
different promoter positions
To quantify PPIR8-driven transgene regulation profiles
associated with promoter positions immediately 50 of the
transgene or within the 30LTRDU3, we replaced EYFP of
pBM60 and pBM94 by the intracellular Bacillus
stearothermophilus-derived heat-stabile a-amylase [amySDS;
(33)]. pBM84 (50LTR-y+-oriSV40-PPT-RRE-MCSI-amySDS-
MCSII-30LTRDU3I-PPIR8-30LTRDU3II)- and pBM97 (50LTR-y+-
oriSV40-PPT-RRE-PPIR8-amySDS-MCSII-3
0LTRDU3I-MCSIII-30
LTRDU3II)-derived lentiviral particles were transduced into
CHO-TWIN1108 and intracellular a-amylase levels quantified
72 h post-transduction (Figure 3A). Both lentivector config-
urations enabled tight a-amylase control and showed similar
induction factors [pBM84, (32); pBM97, (35)]. Yet, the PPIR8-
amySDS configuration outperformed maximum expression
ψ
∆
∆
∆
Figure 1. Plasmid maps of basic SIN lentiviral expression vectors derived from HIV (pBM57) and EIAV (pBM80). pBM57 contains a 50-LTR, an extended
packaging signal (y+), SV40 origins of replication (oriSV40), a central polypurine tract (cPPT), the RRE, anEYFP and an enhancer-free 30LTRDU3). pBM80 harbors a
modified 50-LTR consisting of a CMV-derived enhancer element (ECMV) cloned adjacent to the R-U5 module, an extensive polylinker, a truncated envelope-
encoding gene (DEnv) and an enhancer-free 30-LTR (30LTRDU3). pBM57 is fully compatible with previously reported lentiviral expression vectors and enable
straightforward module swapping (29).
PAGE 5 OF 14 Nucleic Acids Research, 2004, Vol. 32, No. 12 e106
levels of 30LTRDU3-located PPIR8 80-fold (Figure 3B).
Therefore, we chose to use direct promoter-transgene con-
figurations for further analysis.
Lentivectors engineered for streptogramin-responsive
control of secreted protein production
Since tight control of secreted protein therapeutics is a stand-
ard challenge in current gene therapy scenarios, we have eval-
uated conditional expression performance of lentivectors
engineered for streptogramin-responsive expression of the B.
stearothermophilus-derivedsecreteda-amylase [SAMY;(33)],
human VEGF121 (29) and the human model glycoprotein
SEAP (38). pBM96 (50LTR-y+-oriSV40-cPPT-RRE-PPIR8-
SAMY-30LTRDU3)-, pBM104 (50LTR-y+-oriSV40-cPPT-RRE-
PPIR8-VEGF121-3
0LTRDU3)- and pBM105 (50LTR-y+-oriSV40-
cPPT-RRE-PPIR8-SEAP-3
0LTRDU3)-derivedlentiviralparticles
were transduced into CHO-TWIN1108 and respective reporter
protein secretion quantified 72 h post-transduction cultivation
in the presence and absence of regulating streptogramin
antibiotics. All reporter proteins showed equivalent tight
pristinamycin-responsive secretion substantiating the fact
that this lentivector design enables robust expression control
[pBM96 (induction factor 36), PI: 4031 – 480 U/l, +PI:
113 – 14 U/l; pBM104 (induction factor 28), PI: 43 – 3.4
ng/ml, +PI: 1.5 – 0.3 ng/ml; pBM105 (induction factor 30),
PI: 2758 – 325 ng/ml, +PI: 91 – 18.64 ng/ml]. Furthermore,
Figure 2. Lentivector-based regulated expression of fluorescent proteins. (A) Detail representation of streptogramin-responsive transgene modules of HIV- (pBM60;
pBM94) and EIAV- (pBM99) derived lentivectors. 30LTRDU3; enhancer-less 30-LTR; 30LTRDU3I/30LTRDU3II, modified 30LTRDU3; PPIR8, streptogramin-responsive
promoter;DEnv, truncated EIAV envelope-encoding gene. Abbreviation of restriction endonucleases: A, AscI; B, BamHI; Bs, BssHII; C, ClaI; E, EcoRI; F, FseI; H,
HpaI; K, KpnI; M, MluI; N, NheI; No, NotI; Nr, NruI; P, PacI; Pm, PmeI; S, SacII; Sb, SbfI; Sl, SalI; Sg, SgfI; Sh, SphI; Sp, SpeI; Sr, SrfI; Sw, SwaI; X, XbaI; and Xh,
XhoI. (B) EYFP-specific fluorescence micrographs of PIT (pristinamycin-dependent transactivator)-expressing CHO-TWIN1108 transduced with pBM60, pBM94
and pBM99 cultivated for 48 h in the presence (+PI) and absence (PI) of the streptogramin antibiotic PI.
e106 Nucleic Acids Research, 2004, Vol. 32, No. 12 PAGE 6 OF 14
pBM392/pBM104-derived lentiviral particles enabled trans-
duction and VEGF121 regulation in human PBMC (induction
factor 11,PI: 1.2 – 0.1 ng/ml, +PI: 0.1 – 0.0 ng/ml) and mouse
CD4+ cells (induction factor 13, PI 0.8 – 0.1 ng/ml, +PI:
0.1 – 0.0 ng/ml).
Transgene expression switching and adjustability of
streptogramin-responsive SAMY-encoding lentivectors
Switch kinetics, reversibility of expression status and adjust-
ability of transgene expression are key characteristics of any
heterologous transcription control configuration. We have
therefore subjected CHO-TWIN1108 cultures transduced
with pBM96 (50LTR-y+-oriSV40-cPPT-RRE-PPIR8-SAMY-
30LTRDU3)-derived lentiviral particles to changing strepto-
gramin dosing regimes (+PI/+PI/+PI; +PI/+PI/PI; PI/PI/
PI; PI/PI/+PI; +PI/PI/PI; +PI/PI/+PI; PI/+PI/
+PI; PI/+PI/PI) and SAMY expression readouts were
taken at corresponding days 4/7/10. pMF364-derived lenti-
viral particles (50LTR-y+-oriSV40-cPPT-RRE-PhEF1a-SAMY-
30LTRDU3) were used as constitutive control. SAMY
expression was characterized by tight expression switches
as well as complete reversibility of transgene control
(Figure 4A). Also, streptogramin-responsive SEAP expression
encoded on pBM105-derived lentiviral particles can be pre-
cisely titrated to desired levels by defined PI dosing (Figure 4B).
Streptogramin-controlled adipocyte versus osteoblast
differentiation following lentivector-based transduction of
muscle precursor cells
Current gene therapy and tissue engineering initiatives eval-
uate the potential of heterologous gene control systems for
rational reprogramming of desired cell phenotypes following
conditional expression of differentiation-modulating trans-
genes. Transdifferentiation studies require particularly tight
control and set a high standard for artificial transcription con-
trol modalities. Following a multi-step design strategy, we
have configured pBM57 for streptogramin-responsive expres-
sion of the human CCAAT/enhancer-binding protein alpha
(C/EBP-a) (pBM103; 50LTR-y+-oriSV40-PPT-RRE-PPIR8-c/
ebp-a-MCSII-30LTRDU3I-MCSIII-30LTRDU3II) (Figure 5A).
Figure 3. Comparative streptogramin-responsive expression profiling of lentivectors with different promoter-transgene configurations. (A) Detail projection of
isogenic lentivectors pBM84 and pBM97. Although pBM84 contains the streptogramin-responsive promoter (PPIR8) within a modified 3
0-LTR (30LTRDU3;
30LTRDU3I; 30LTRDU3II) and requires reverse transcription and chromosomal integration for PPIR-driven expression of the intracellular reporter gene amySDS
(signal peptide-free B.stearothermophilus-derived a-amylase), pBM97 contains a central PPIR8- amySDS expression configuration. (see caption of Figure 2 for
abbreviation of restriction endonucleases). (B) Quantitative a-amylase profiling of PIT-producing CHO-TWIN1108 transduced with pMF84-/pMF97-derived
lentiviral particles and cultivated for 48 h in the presence (+) and absence () of PI. pBM84-derived lentiviral particles reached 32-fold induction whereas cells
transduced with pBM97 lentivectors showed an induction factor of 35.
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To induce differential differentiation pBM103-transduced
C2C12PIT/tTA
, myoblasts were cultivated in the presence
(repression of c/ebp-a) and absence (induction of c/ebp-a)
of PI. Indeed, following repression of c/ebp-a, C2C12PIT/tTA
differentiated into adipocytes following 14 days cultivation
period in DEI-containing medium [Figure 5B; (30)]. In con-
trast, maintenance in streptogramin-free medium resulted in
ongoing C/EBP-a expression, which differentiated engineered
C2C12PIT/tTA cell populations into osteoblasts (Figure 5C).
Transduction of chicken embryos using lentiviral particles
transgenic for streptogramin-adjustable expression of
human VEGF
To validate lentivector-based streptrogramin-responsive trans-
gene expression in vivo, we co-transduced chicken CAM by
distinct lentiviral particles encoding (i) constitutive PIT
(pMF392) and (ii) PIT-responsive PPIR8-driven VEGF121
(pBM104) expression, and scored neovascularization as well
as vessel morphology after administration of different amounts
of pristinamycin. CAMs cultivated under PI-free conditions
exhibited VEGF-mediated induction of new blood vessels
exemplified by increased formation of numerous arterioles
and venules (Figure 6A and B). Also, the hierarchical, tree-
like structure of the supplying vessels was disturbed and the
multitude of arterioles and venules adopted an irregular tortuous
shape associated with atypical delta- or brush-like vessel end
points. The VEGF-induced effect was confined to a 4 mm radius
around the lentiviral particle application sites and could not be
observed on the same CAM beyond this perimeter (Figure 6C).
Following administration of increasing amounts of PI (6, 30, 60
mg),VEGF121 expressionwasgraduallydecreased to full repres-
sion that resulted in native vascularization profiles and vessel
morphologies at the application site (Figure 6D–F).
Autoregulated streptogramin-responsive lentivectors
Owing to the binary nature of the streptogramin-responsive
transcription control modality lentivector-based engineering of
desired target cells requires co-transduction of lentiviral particles
transgenicforconstitutivePIT(pMF392)andPPIR8-drivenEYFP
expression (pBM60, pBM94). However, as exemplified by
infection of primary NHDF and CHO-K1 cells co-transduction
provided excellent regulation profiles but at lower efficiencies
Figure 4. Lentivector-based streptogramin-responsive transgene expression switching kinetics and adjustability in CHO-K1 cell derivatives. (A) SAMY expression
of different cultures of CHO-TWIN1108 transduced with pBM96-derived lentiviral particles (1–8) was switched at days 4, 7 and 10 post-transduction (maximum
induction factor 209). CHO-TWIN1108 transduced with pMF364-derived lentiviral particles was used as constitutive control. (B) Adjustable SEAP expression of
CHO-TWIN1108 transduced with pBM105-derived lentiviral particles and cultivated for 48 h in the medium supplemented with indicated PI concentrations
(maximum induction factor 20).
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Figure 6. In vivo examination of microvascular growth in the CAM of 12-day-old chicken embryos 72 h post co-transduction with pBM104- [2 ml (8.7 · 106 cfu)
producing 106.66 – 7.84 ng/ml VEGF121 in CHO-K1-derived cells in 48 h] and pMF392- (1 ml; 1.5 · 105 cfu) derived lentiviral particles encoding the human
VEGF121. Lentivirus application induced an angiogenic response with atypical (brush- and delta-like) end point patterns (arrows) and irregular tortuous vessel shape
(arrowhead) within a perimeter of 4 mm when no antibiotic was present [(A) 50·magnification; (B) 100·magnification]. Beyond this boundary, the VEGF121-based
effects fade in a distance-dependent manner and are undetectable at 15 mm (C). Following administration of increasing amounts of VEGF121-repressing PI
concentrations post-transduction VEGF121-induced angiogenesis gradually decreased [(D) 6 mg (50· magnification); (E) 30 mg (50· magnification)] to full
repression which resulted in native vascularization profiles and vessel morphologies at the application site [(F) 60 mg (50· magnification); dashed line].
Figure 5. Streptogramin-responsive differential adipocyte versus myoblast versus osteoblast differentiation of C2C12-derived cell lines transduced with pBM103-
derived lentiviral particles engineered for streptogramin-responsive expression of the CCAAT/enhancer-binding protein alpha (C/EBP-a). (A) Schematic detail
representation of pBM103 harboring a c/ebp-a cassette driven by the streptogramin-responsive promoter (PPIR8) and terminated by an enhancer-free 30-LTR
(30LTRDU3) (see caption of Figure 2 for abbreviation of restriction endonucleases). (B) Light micrographs of C2C12PIT/tTA transduced with pBM103-derived
lentiviral particles and cultivated for 14 days in DEI-supplemented PI-containing (+PI) or PI-free medium. Cultures were stained with Oil Red O to visualize
triglyceride droplets exclusively produced by adipocytes (PI, induction of c/ebp-a). (C) Microscopic analysis of C2C12PIT/tTA transduced with pBM103-derived
lentiviral particles and cultivated for 5 days in the presence (+) and absence () of PI prior to specific staining of osteoblasts (blue; PI, induction of c/ebp-a).
C/EBP-a has recently been shown to induce osteogenesis in C2C12-derived myoblast cultures (30).
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(Figure 7) compared to mono-transductions (Figure 2B) (24). In
addition to compromising transduction efficiencies, co-integra-
tion of transactivator- and transgene-encoding proviruses may
result in deregulated transgene expression owing to interference
between the operator contained in the transactivator-driving
promoter and the antibiotic-responsive promoter. To provide
interference-free streptogramin-responsive transgene expres-
sion following transduction of a single lentiviral particle type,
we designed the followingclasses ofbidirectional autoregulated
lentiviral expression vectors: (i) pBM93 (50LTR-y+-oriSV40-
cPPT-RRE-pAI-EYFP PhCMVmin-PTR-Phsp70min!PIT-pAII-
30LTRDU3) and pBM126 (50LTR-y+-oriSV40-cPPT-RRE-pAI-
SEAP PhCMVmin-PTR-Phsp70min!PIT-pAII-30LTRDU3), (ii)
pBM98 (50LTR-y+-oriSV40-cPPT-RRE-pAI-EYFP PhCMV-
hCMVmin-PTR-Phsp70min!PIT-30LTRDU3) and pBM127
(5 0LTR-y+-oriSV40-cPPT-RRE-pAI-SEAP PhCMVmin-PTR-
Phsp70min!PIT-30LTRDU3) and (iii) pBM106 (50LTR-y+-
oriSV40-cPPT-RRE-EYFP PhCMVmin-PTR-Phsp70min!PIT-
30LTRDU3) and pBM128 (50LTR-y+-oriSV40-cPPT-RRE-
SEAP PhCMVmin-PTR-Phsp70min!PIT-30LTRDU3) (Figure
8A). All autoregulated lentiviral expression vectors contain a
central asymmetric bidirectional streptogramin-responsive pro-
moter consisting of a central PIT-specific PTR operator site
flanked by minimal versions of the human cytomegalovirus
immediate early (PhCMVmin) and the Drosophila heat-shock pro-
tein 70 (Phsp70min) promoters. The stronger PhCMVmin was
arranged to drive EYFP or SEAP expression whereas Phsp70min
wasset tomaintain theautoregulatorycircuitviaPITexpression.
pBM93/pBM126, pBM98/pBM127 and pMF106/pBM128
differ in their configuration of synthetic minimal polyadenyla-
tion sites. Although the divergent expression units of pBM93
and pBM126 are terminated by synthetic size-optimized pA
sites (pAI, pAII), only the EYFP/SEAP expression unit of
pBM98 and pBM127 harbor a pA (pAI) site whereas
pBM106 and pBM128 are devoid of any pA. Autoregulated
expression is kicked off by leaky expression of the bidirectional
promoter which produces PIT at regulation-effective concen-
trations which is either inactivated in the presence of PI or may
bind and activate the bidirectional promoter in the absence of
regulating streptogramins thereby initiating a positive feed-for-
ward circuit expressing PIT as well as divergently encoded
EYFP/SEAP. Following transduction of human HT-1080 and
CHO-K1 with pBM93-, pBM98- and pBM106-derived lenti-
viral particles, streptogramin-responsive EYFP expression
could be observed for all lentivectors (Figure 8B and C;
Table IV). Furthermore, streptogramin-regulatable SEAP
expression was quantified following transduction of
pBM126-, pBM127- and pBM128- derived lentiviral particles
into K-562 [pBM126,PI: 345.5 – 18.5 ng/ml, +PI: 35.1 – 0.5
ng/ml (induction factor 10); pBM127, PI: 219.7 – 9.5 ng/ml,
+PI: 27.4 – 2.1 ng/ml (induction factor 8); pBM128, PI:
122.3 – 6.1 ng/ml, +PI, 15.0 – 0.4 ng/ml (induction factor 8)].
DISCUSSION
In the past decade, viral transduction systems have witnessed
dramatic advances including implementation of heterologous
Figure 7. Fluorescence micrographs of streptogramin-responsive EYFP expression in CHO-K1 and primary NHDF following co-transduction of pMF392-
[engineered for constitutive expression of the pristinamycin-dependent transactivator (PIT)] and pBM60- [encoding the streptogramin-responsive promoter
(PPIR8) within a modified 3
0-LTR (30LTRDU3)] or pBM94- (harboring a direct PPIR8-EYFP expression unit) derived lentiviral particles and cultivation in the
presence (+) and absence () of PI.
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Figure 8. Autoregulated streptogramin-responsive transgene expression following transduction of a single lentiviral particle type into CHO-K1 and human HT-1080
cells. (A) Schematic representation of the bidirectional streptogramin-responsive autoregulated EYFP expression units of lentivectors pBM93, pBM98 and pBM106.
At the center of these lentivectors resides an asymmetric bidirectional promoter containing a PIT (pristinamycin-dependent transactivator)-specific operator module
(PTR) flanked by minimal versions of the human CMV immediate early (PhCMVmin) and the Drosophila heat-shock protein 70 (Phsp70min) promoters. Although PTR-
Phsp70min initiates and maintains the autoregulated feedback circuit by driving PIT expression, PTR-PhCMVmin modulates EYFP transcription. pBM93, pBM98 and
pBM106 differ in the configuration of their synthetic size-optimized polyadenylation sites (pAI, pAII). Whereas pBM93 contains two pAs flanking the bidirectional
expression unit, only pAI terminates EYFP transcripts in pBM98 and pBM106 remains pA-free (see caption of Figure 2 for abbreviation of restriction endonucleases).
pBM93-, pBM98- and pBM106-derived lentiviral particles were transduced into CHO-K1 (B) and HT-1080 cells (C) and grown for 48 h in the absence () or
presence (+) of the regulating streptogramin antibiotic PI prior to microscopical and quantitative analyses of EYFP expression profiles: CHO-K1 (pBM93, PI:
12.3 – 1.0, +PI: 0.9 – 0.3 RLU; pBM98,PI: 15.6 – 1.7, +PI: 0.9 – 0.2 RLU; pBM106,PI: 9.2 – 0.2, +PI: 1.0 – 0.2 RLU), HT-1080 (pBM93,PI: 11.8 – 0.8, +PI:
1.3 – 0.3 RLU; pBM98, PI: 21.1 – 1.8, +PI: 1.9 – 0.1 RLU; pBM106, PI: 17.4 – 0.5, +PI: 2.1 – 0.5 RLU).
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transgene modulation (25,39–48). For lentivirus-based trans-
duction arrangements, systems responsive to tetracycline anti-
biotics (the TET systems) have been most popular and were
used in the following basic/optimized configurations: (i)
classic TETOFF system (24,49–54), (ii) reverse tetracycline-
dependent TETON system (55–59) and (iii) the TetR-based
TETON technology (14,60,61). Lentiviral transduction systems
have been engineered for tetracycline-responsive gene expres-
sion to (i) enable construction of stable helper cell lines
producing pseudotyping VSV-G in a timely manner and/or
at subtoxic doses (15,52,62), (ii) design chimeric adeno-
lentiviral vectors which produce lentiviral particles from trans-
genic lentiviruses in a tetracycline-responsive manner (57),
(iii) generate conditionally replicating HIV-based vectors
for vaccination (56,59), (iv) mediate tetracycline-inducible/
repressible transgene expression (24,50,51,53,54,58,60,63)
and (v) modulate siRNA-based knockdown of endogenous
genes (14,63).
Pioneering tetracycline-responsive expression configura-
tions were based on two separate vectors one of which
included a constitutive tetracycline-dependent transactivator
and the other contained a tetracycline-responsive promoter-
driven transgene expression unit engineered into a non-SIN
lentiviral backbone. Owing to their non-SIN structure
first-generation transgene-controlled lentivectors exhibited
increased leakiness resulting from LTR-associated enhancer
interference with tetracycline-responsive promoters (50–52).
SIN-based tetracycline-responsive lentivectors containing
an enhancer deletion in the 30 LTRDU3 provided improved
induction factors based on interference-free repression.
Following the proven design concept of the tetracycline-
responsive expression technology, we have recently developed
a human-compatible mammalian transcription control system
responsive to clinically licensed streptogramin antibiotics
(26). This so-called PIP system included several inducible/
repressible configurations all of which showed excellent
regulation performance in a variety of different cell lines
and human primary cells as well as in mice (26–28,31,
42,64). Also, PIP systems were fully compatible with TET
and other antibiotic-adjustable transcription control systems
and could be used for differential fine-tuning of different
transgene activities (28,31,42). Following configuration into
a lentiviral expression context, the PIP system showed excel-
lent streptogramin-responsive transgene regulation perfor-
mance, including tight repression, high-level expression,
reversibility and adjustability in a variety of mammalian/
human cell lines and primary cells. Efficiency of the strepto-
gramin-responsive lentivector design was exemplified by dif-
ferential differentiation reprogramming of muscle cells into fat
or bone phenotypes as well as conditional vascularization of
chicken embryos. Comparative regulation profiling of isogenic
lentivectors either encoding a direct PPIR8-transgene expres-
sion unit or harboring PPIR8 within a SIN-modified 3
0LTRDU3
revealed the former configuration to enable almost two orders
of magnitude higher transgene expression levels at comparable
induction factors. Direct comparison of isogenic HIV- and
EIAV-derived lentiviral vectors engineered for direct PPIR8-
EYFP expression suggested lower EIAV-mediated transduc-
tion rates although both systems provided excellent regulation
performance in the CHO-K1-derived cell lines. Although out-
performed by HIV-derived lentivectors at first sight, this
pioneering example of regulated transgene expression in
non-primate lentiviruses may hold great promise for clinical
application because of minimal risk associated with EIAV-
based therapeutic interventions.
Owing to the binary nature of currently available transcrip-
tion control systems, transduction of regulated transgene
expression is typically realized by simultaneous co-infection
of two separate lentiviral particles, one encoding the antibio-
tic-responsive transactivator and the second one harboring the
transactivator-responsive transgene expression unit. Since co-
transduction rates are typically lower and require a higher
multiplicity of infection compared to transduction using a
single lentiviral particle type design of single lentivector-
based strategies for adjustable therapeutic interventions is
the current clinical priority. First-generation one-vector-
based regulated lentiviral transgene configurations included
placement of independent transactivator- and transgene-
encoding expression units on the same lentivector (51). How-
ever, this configuration mediated significant leaky expression
due to combinatorial interference of the enhancers contained
in the transactivator-driving promoter and the 30-LTR. Auto-
regulated expression configurations in which transactivator
and transgene are co-expressed in a coordinated manner repre-
sent the only a priori interference-free regulated expression
configuration (42,65). Recently, Ogueta et al. (60) have engi-
neered an autoregulatory lentiviral one-vector design by clon-
ing the tetracycline repressor (TetR) and the gene of interest
into a dicistronic configuration driven by the tetR-repressible
promoter (PhCMV-tetO2-EGFP-IRES-TetR; tetO2, dimeric
TetR-specific operator; EGFP, enhanced green fluorescent
protein; and IRES, internal ribosome entry site). Although
this inducible autoregulated lentiviral expression system
enabled excellent regulation performance, the restricted tissue
tropism of IRES elements as well as the lag phase required to
accumulate repression-effective TetR concentrations may
limit some applications. The bidirectional autoregulated cas-
sette presented here addresses aforementioned limitations by
enabling streptogramin-responsive transgene expression in the
most compact and efficient format.
All of the currently available HIV-1-based expression vec-
tors tailored for adjustable transgene expression in mammalian
cells exhibit residual transcription activity under repressed
conditions (42,65). Although such basal expression remains
an inherent characteristic of any heterologous transcription
control system (42,65), leaky expression is accentuated by
HIV-1’s integration preference for transcriptionally active
hot spots, which may interfere with desired transgene control
to a significant extent (42,65).
Combination of robust transgene control modalities with
latest generation lentiviral transduction systems will further
advance molecular interventions for gene therapy and tissue
engineering.
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